Phase 1 · Prior Art & Diagnostic Precedents

Worksheet 3.1: Diagnostic Precedents & Competitive Benchmark Matrix

Systematically deconstruct incumbent diagnostic systems, clinical gold standards, and cutting-edge laboratory precedents. Benchmark their physical transduction principles, spatial/temporal performance boundaries, clinical workflows, and cost footprints to articulate your project's competitive advantage and biophysical "Why Now?" enabling innovation.

The Engineering Purpose of Precedent Benchmarking: In biomedical device development, no system is conceived in a vacuum. Panel reviewers and the FDA evaluate your system relative to existing clinical standards and predicate devices:

Biophysical Trade-off Envelope: Understand why prior systems made specific trade-offs (e.g., SQUID MEG sacrificed portability for femtotesla sensitivity; 7T MRI traded SAR safety limits for sub-millimeter anatomical SNR).
The "Why Now?" Threshold: Breakthrough projects do not simply want to do better; they leverage a recent enabling technology (e.g. quantum optically pumped magnetometers, room-temperature superconductors, edge TPUs, silicon photomultipliers) that was historically unavailable to prior inventors.
Regulatory Substantial Equivalence: Identifying a legally marketed 510(k) predicate benchmark establishes an accelerated path to FDA clearance.

1 Team & Clinical Baseline Context

Re-anchor your competitive benchmarking in the specific disease pathology and clinical workflow bottleneck defined in Weeks 1 & 2.

Team Identifier & Project Title

Team Members & Engineering Disciplines

Target Indication for Use & Primary Clinical Bottleneck

Current Clinical Gold Standard

Critical Failure Modes of Gold Standard

2 Competitive Benchmark Matrix

Benchmark 3 to 5 predecessor diagnostic technologies (commercial clinical systems, historical predicates, or emerging lab prototypes). Detail their operating physics, spatial/temporal performance, clinical footprint, and regulatory classifications.

Precedent System & Manufacturer	Biophysical Modality & Principle	Spatial & Temporal Resolution	Diagnostic Performance (Sens / Spec)	Siting, Footprint & Safety	Capital & Exam Cost	FDA Regulatory Status & 510(k)	Action

💡 Tip for Phase 1 Dossier: Ensure you include at least one ultra-high-resolution standard (e.g. 7T MRI), one electrophysiological standard (e.g. MEG or sEEG), and one accessible/point-of-care system (e.g. low-field MRI, high-density EEG, or portable fNIRS) to span the full engineering envelope.

3 Multi-Dimensional Trade-Off Comparison

Compare how your proposed system targets an optimal operating point across the six fundamental axes of neurodiagnostic system performance.

1. Spatial Precision Micro-Structure

Conventional Standard: 3.0 – 5.0 mm

Proposed Target: ≤ 1.2 mm

Resolves micro-dysplastic gyral architectures buried in deep sulcal folds without intracranial craniotomy.

2. Temporal Speed Fast Dynamics

Conventional Standard: 1.0 – 2.0 s (fMRI)

Proposed Target: ≥ 1,000 Hz (<1 ms)

Captures fast pathological high-frequency oscillations (HFOs 80–500 Hz) to separate primary seizure onset from secondary spread.

3. Siting & Cryogens Infrastructure

Conventional Standard: MSR + Liquid He (4K)

Proposed Target: Zero-Cryogen / Ambient

Eliminates reliance on volatile liquid helium supply chains and enables rigid/flexible sensors to touch the scalp directly.

4. Patient Motion Usability

Conventional Standard: Immobilized (<1 mm)

Proposed Target: Wearable / Tracking

Accommodates pediatric, claustrophobic, and post-ictal patients who cannot remain motionless in fixed scanner bores.

5. Capital & Exam Cost Economics

Conventional Standard: $3M – $8M+ Capital

Proposed Target: < $600k Capital

Enables regional neurology centers and outpatient clinics to conduct pre-surgical workups without tertiary mega-center transfer.

6. Invasive Risk Profile Patient Safety

Conventional Standard: Burr-hole Craniotomy

Proposed Target: 100% Non-Invasive

Eliminates anesthesia requirements and reduces intracranial hemorrhage/infection risks from ~3% to 0%.

4 The "Why Now?" Biophysical Catalyst

Diagnose why previous engineering efforts failed or stalled, and identify the technological breakthrough that makes your proposed system feasible today.

Fundamental Biophysical Bottleneck of Incumbent Precedents

The "Why Now?" Enabling Technology (Recent Breakthrough)

Defensibility & Competitive Moat

5 Predicate Device & Substantial Equivalence Alignment

Select your primary FDA 510(k) predicate benchmark and justify substantial equivalence.

Designated Primary Predicate Device

Predicate 510(k) / PMA / De Novo Number

Substantial Equivalence Comparison (Intended Use & Operating Principle)

Technological Differences & Non-Inferiority Justification

6 Phase 1 Dossier Synthesis (Section 2: Prior Art & Benchmarking)

Synthesize your competitive benchmarking findings into formal prose ready for direct inclusion into Section 2 of your Phase 1 Deliverable Dossier.

Executive Prior Art & Competitive Landscape Statement